ZYX

Across TCGA pan-cancer cohorts, ZYX RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated ZYX data layer compared with 6 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ZYX RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ZYX expression acts as an unfavorable survival marker, although some lineages such as ESCA and SKCM show a favorable association.

MESO, LGG, and ESCA are the cancer types where ZYX RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.243	0.527	<.001	71	view →
LGG	DFS	Median	All	0.337	0.491	<.001	54	view →
ESCA	OS	Quartile	III,IV	0.701	0.361	.001	46	view →
LUSC	OS	Tertile	All	0.565	0.707	.007	34	view →
ACC	DFS	Tertile	All	0.162	0.624	.002	33	view →
SKCM	DFS	Median	IV	0.763	0.187	.006	24	view →
LUAD	DFS	Tertile	II,III,IV	0.527	0.787	.002	24	view →
COAD	DFS	Median	IV	0.349	0.631	<.001	23	view →
KIRC	DFS	Quartile	II,III,IV	0.636	0.840	.011	18	view →
LIHC	DFS	Tertile	All	0.366	0.612	.008	16	view →
STAD	OS	Tertile	IV	0.182	0.711	.038	12	view →
UCEC	DFS	Median	III,IV	0.674	0.467	.032	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

ZYX–MESO (OS)

Open the MESO breakdown →